Iowa Gov. Kim Reynolds signs drug pricing bill into law
Jun. 11—The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced.
Third-party health care companies will face new restrictions designed to constrain prescription drug costs and protect rural pharmacies under legislation signed into law Wednesday by Gov.
Senate File 383 places limits on pharmacy benefit managers — known as PBMs, the companies that function as intermediaries between insurance providers and drug manufacturers.
It seeks to eliminate "spread pricing," where PBMs keep the difference between what they pay the pharmacy and what they charge the insurance company.
Under the legislation, all prescription drug contracts in
Reynolds, in a statement, said she signed the bill "in an effort to continue improving our health care system by bringing greater accountability to the role" of PBMs. The governor said the legislation builds on her rural health care bill passed and signed into law earlier this year, and provides a "fairer, more transparent and accessible health care system for all."
Pharmacies and other health care organizations support the legislation, which they say will help protect pharmacies from closure.
Last year, more than 30 pharmacies closed in
The
"For too long, PBMs have put profits over patients,"
The pharmacy association contends concerns that health insurance premiums will increase have not proved true in states with similar legislation.
Reynolds administration will monitor for 'unintended consequences'
Reynolds said the law will aid independent community pharmacies that have struggled because of PBM practices she and lawmakers argue are contributing to rising overall health care costs through "opaque, one-sided" pricing and rebate strategies.
PBMs play a central role in the pharmaceutical supply chain, Reynolds said, by negotiating drug prices, determining which pharmacies will be included in a prescription drug plan's network and how much those pharmacies will be paid for their services. PBMs also regulate which drugs are covered under a specific plan and set co-pays, negotiate rebates with drug manufacturers and process prescription medication claims, for a fee, for insurance companies, among other roles.
Three of the companies — CVS Caremark,
"This vertical integration gives them outsized power over which medication patients receive and what they pay — often resulting in unaffordable drug costs, difficult choices for families, and reimbursement below pharmacy acquisition cost," the governor said in her statement.
Reynolds, though, said the legislation is not the end. She said her administration will closely monitor implementation "to mitigate and ensure that any unintended consequences for private employers are addressed."
"The complexity and lack of verifiable data made signing this bill a difficult decision," she said.
The governor said her office also will be launching a reverse auction — where sellers bid against each other to offer the lowest price for a product or service to a single buyer — to keep costs as low as possible for the state and its employees.
Rep.
In a joint statement urging Reynolds to veto the bill, the
"As
What the bill will do
In addition to being required to pay small pharmacies a dispensing fee, PBMs will be prohibited from:
— Limiting or disincentivizing an individual from selecting a pharmacy or pharmacist of their choice;
— Designating a prescription drug as a specialty drug to prevent a person from accessing the prescription;
— Requiring a customer to purchase prescription drugs or other services through a mail order pharmacy, or from charging more for prescription drugs or other services than if they were purchased from any other pharmacy;
— Or reimbursing small pharmacies less than the national or
The bill also requires PBMs to provide an appeals process for pharmacies to challenge reimbursement rates for specific prescriptions and would allow pharmacies to decline to dispense a prescription to a person if the pharmacy would be reimbursed less for the prescription than the cost to the pharmacy.
It also prohibits PBMs from discriminating against pharmacies or pharmacists regarding participation, referrals, reimbursements of a covered service, or indemnification if the pharmacist is acting within its scope of practice.
Comments: (319) 398-8499; [email protected]
© 2025 The Gazette (Cedar Rapids, Iowa). Visit thegazette.com. Distributed by Tribune Content Agency, LLC.



Reports Summarize Heart Attack Study Results from Dartmouth College (Incorporating Behavioral Science In Medication Adherence Communication: a Randomized Clinical Trial): Heart Disorders and Diseases – Heart Attack
Costs will spike, 100,000 Coloradans will lose health coverage if Trump spending bill passes, regulators say
Advisor News
- Addressing the ‘menopause tax:’ A guide for advisors with female clients
- Alternative investments in 401(k)s: What advisors must know
- The modern advisor: Merging income, insurance, and investments
- Financial shocks, caregiving gaps and inflation pressures persist
- Americans unprepared for increased longevity
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Aspida Life and WealthVest Offer a Powerful New Guaranteed Income Product with the WealthLock® Income Builder
- Lack of digital tools drives wedge between insurers, advisors
- LIMRA: Annuity sales notch 10th consecutive $100B+ quarter
- AIG to sell remaining shares in Corebridge Financial
More Annuity NewsHealth/Employee Benefits News
- We can't afford to let Democrats lead health care 'reform' | Opinion
- Expanding Medicaid coverage lowered death rates for young adults with kidney failure
- GLP-1s: Rewriting the relationship between pharmacy benefits and stop-loss
- Studies from Denise Wolff et al Have Provided New Data on Atopic Dermatitis (AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitis): Skin Diseases and Conditions – Atopic Dermatitis
- New Clinical Trials and Studies Findings from RAND Corporation Described (Benefit design and consumer information: results from a randomized trial): Clinical Research – Clinical Trials and Studies
More Health/Employee Benefits NewsLife Insurance News
- 3 ways AI can help close the gap for women’s insurance coverage
- Best’s Market Segment Report: AM Best Revises Outlook on Italy’s Life Insurance Segment to Stable From Negative
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Dan Scholz to receive NAIFA’s Terry Headley Lifetime Defender Award
- Best’s Special Report: US Property/Casualty and Health Insurers Exceed Cost of Capital; Life Insurers Narrowly Miss
More Life Insurance News